Effects of 800mg of Rhodiola Rosea in Attention in Adults With Attention-Deficit/Hyperactivity Disorder

• Status: Unknown status
• Trial end date: 2021-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the use of Rhodiola rosea in the attention of adults with Attention Deficit/Hyperactivity Disorder (ADHD). Half of participants will receive Rhodiola rosea 800mg, while the other half will receive 800mg of placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre

Criteria

Inclusion Criteria:

• Fulfillment of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5) diagnostic criteria for ADHD in Adults

• Intelligence Quotient (IQ) above 70

• Eligibility to Rhodiola rosea

Exclusion Criteria:

• clinical contraindication to Rhodiola rosea

• any unstable chronic illness without proper treatment (hypertension, heart, kidney or liver disease, etc)

• any significant neurological disease (delirium, dementia, epilepsy, AIDS, head trauma, multiple sclerosis, stroke, etc)

• unstable psychiatric comorbidities requiring immediate treatment (risk of suicide, current Substance Use Disorder, etc.)

• pregnant, nursing or absence of reliable contraception

• current use of nicotine (<30 days)

• use of anticoagulants

• current use of any psychoactive drug (<30 days)

• prior use of stimulants

• current or lifetime psychosis

• current or lifetime bipolar disorder